Cosmo Pharmaceuticals N.V. (CMOPF)
USD 55.0
(0.0%)
USD 55.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 124.94 Million EUR | -61.36% |
| 2022 | 323.34 Million USD | -5.07% |
| 2021 | 340.6 Million USD | 37.1% |
| 2020 | 248.43 Million USD | 15.62% |
| 2019 | 214.87 Million USD | 3.95% |
| 2018 | 206.71 Million EUR | 517.98% |
| 2017 | 33.45 Million EUR | 13.61% |
| 2016 | 29.44 Million EUR | -20.97% |
| 2015 | 37.25 Million EUR | -49.2% |
| 2014 | 73.33 Million EUR | 220.94% |
| 2013 | 22.84 Million EUR | -16.13% |
| 2012 | 27.24 Million EUR | 86.55% |
| 2011 | 14.6 Million EUR | -56.35% |
| 2010 | 33.45 Million EUR | 186.73% |
| 2009 | 11.66 Million EUR | -19.68% |
| 2008 | 14.52 Million EUR | 20.26% |
| 2007 | 12.08 Million EUR | -41.28% |
| 2006 | 20.57 Million EUR | -25.4% |
| 2005 | 27.58 Million EUR | 13.3% |
| 2004 | 24.34 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 132.86 Million EUR | 6.34% |
| 2024 Q2 | 132.86 Million EUR | 0.0% |
| 2023 Q2 | 333.16 Million USD | 11.56% |
| 2023 FY | 124.94 Million EUR | -61.36% |
| 2023 Q1 | 298.65 Million EUR | -7.63% |
| 2023 Q3 | 124.94 Million EUR | -62.5% |
| 2023 Q4 | 124.94 Million EUR | 0.0% |
| 2022 Q4 | 323.34 Million USD | 9.31% |
| 2022 FY | 323.34 Million USD | -5.07% |
| 2022 Q1 | 327.5 Million EUR | 11.82% |
| 2022 Q2 | 309.86 Million EUR | -5.39% |
| 2022 Q3 | 295.8 Million EUR | -4.54% |
| 2021 Q1 | 224.8 Million EUR | 14.67% |
| 2021 FY | 340.6 Million USD | 37.1% |
| 2021 Q2 | 191.75 Million EUR | -14.7% |
| 2021 Q3 | 339.22 Million EUR | 76.9% |
| 2021 Q4 | 292.88 Million EUR | -13.66% |
| 2020 Q4 | 196.03 Million EUR | -14.72% |
| 2020 FY | 248.43 Million USD | 15.62% |
| 2020 Q2 | 191.17 Million EUR | -9.26% |
| 2020 Q3 | 229.87 Million EUR | 20.24% |
| 2020 Q1 | 210.68 Million EUR | 10.06% |
| 2019 Q3 | 208.66 Million EUR | 9.61% |
| 2019 FY | 214.87 Million USD | 3.95% |
| 2019 Q1 | 213.53 Million EUR | 18.09% |
| 2019 Q2 | 190.36 Million EUR | -10.85% |
| 2019 Q4 | 191.42 Million EUR | -8.26% |
| 2018 FY | 206.71 Million EUR | 517.98% |
| 2018 Q3 | 209.92 Million EUR | 804.08% |
| 2018 Q2 | 23.22 Million EUR | -18.82% |
| 2018 Q1 | 28.6 Million EUR | 2.68% |
| 2018 Q4 | 180.83 Million EUR | -13.86% |
| 2017 Q4 | 27.85 Million EUR | -15.39% |
| 2017 Q2 | 26.55 Million EUR | -6.27% |
| 2017 Q1 | 28.32 Million EUR | 1.48% |
| 2017 FY | 33.45 Million EUR | 13.61% |
| 2017 Q3 | 32.92 Million EUR | 23.99% |
| 2016 Q4 | 27.91 Million EUR | -10.97% |
| 2016 Q2 | 38.2 Million EUR | -12.19% |
| 2016 Q1 | 43.5 Million EUR | 26.86% |
| 2016 FY | 29.44 Million EUR | -20.97% |
| 2016 Q3 | 31.35 Million EUR | -17.92% |
| 2015 Q2 | 58.73 Million EUR | -6.91% |
| 2015 FY | 37.25 Million EUR | -49.2% |
| 2015 Q4 | 34.29 Million EUR | -10.39% |
| 2015 Q3 | 38.27 Million EUR | -34.84% |
| 2015 Q1 | 63.09 Million EUR | -13.96% |
| 2014 FY | 73.33 Million EUR | 220.94% |
| 2014 Q4 | 73.33 Million EUR | -20.76% |
| 2014 Q3 | 92.55 Million EUR | 276.07% |
| 2014 Q2 | 24.61 Million EUR | -27.42% |
| 2014 Q1 | 33.9 Million EUR | 48.41% |
| 2013 Q3 | 30.92 Million EUR | 23.66% |
| 2013 FY | 22.84 Million EUR | -16.13% |
| 2013 Q4 | 22.84 Million EUR | -26.11% |
| 2013 Q2 | 25 Million EUR | -21.95% |
| 2013 Q1 | 32.04 Million EUR | 17.62% |
| 2012 Q4 | 27.24 Million EUR | 0.0% |
| 2012 Q2 | 15.48 Million EUR | 0.0% |
| 2012 FY | 27.24 Million EUR | 86.55% |
| 2011 Q2 | 32.27 Million EUR | 0.0% |
| 2011 FY | 14.6 Million EUR | -56.35% |
| 2011 Q4 | 14.6 Million EUR | 0.0% |
| 2010 Q2 | 36.73 Million EUR | 0.0% |
| 2010 Q4 | 33.45 Million EUR | 0.0% |
| 2010 FY | 33.45 Million EUR | 186.73% |
| 2009 FY | 11.66 Million EUR | -19.68% |
| 2009 Q4 | 11.66 Million EUR | 0.0% |
| 2008 FY | 14.52 Million EUR | 20.26% |
| 2007 FY | 12.08 Million EUR | -41.28% |
| 2006 FY | 20.57 Million EUR | -25.4% |
| 2005 FY | 27.58 Million EUR | 13.3% |
| 2004 FY | 24.34 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | 99.798% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | 99.81% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | 91.886% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -84.755% |
| Novartis AG | 53.19 Billion USD | 99.765% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | 51.182% |